Vitrafy Life Sciences (VFY) Q2 2025 TU earnings summary

Key achievements and business development

• Successfully listed on the ASX in November 2024, raising $35.0m to fund growth initiatives and commercialisation.

• Customer validation studies in animal and human health are progressing well, with results meeting or exceeding expectations.

• North American expansion underway, including recruitment of business development, regulatory, and commercial sales talent.

• Additional business development opportunities in high-impact application areas are being pursued.

Operational and scientific progress

• Aquaculture: Achieved 65% fertilisation rate with cryopreserved salmon milt, outperforming existing technologies.

• Bovine: Internal testing showed 64% post-thaw motility using Vitrafy technology, a 31% improvement over industry standards.

• Collaboration with Select Sires, Inc. advancing to a paid, higher-volume cryopreservation program in Q4 FY2025.

• Human health: Blood platelets project with US Army Institute of Surgical Research commenced, with results expected in Q4 FY2025.

• Ongoing discussions in cell & gene therapy to expand technology adoption.

Product and organisational development

• Development of Vitrafy Cryopreservation Unit 2.0 and LifeChain software progressing on schedule and budget.

• Partnership with Planet Innovation for VCU2.0 design and US manufacturing preparation.

• LifeChain software upgrade underway to enhance scalability and data insights, targeted for completion in H1 FY2026.

• US-based contractor with cell and gene therapy expertise appointed to drive lead generation.